DMD Phase 2 Results in Q4 = Potential 5000% Gem

Antisense Therapeutics =Market cap $18 Million / Phase 2 Results of DMD Trial expected next Quarter / Former Chairman of Sarepta and inventors of Eteplirsen on board of this small company = Could be the next Potential 5000% Gem like Sarepta (SRPT) , Its also a super attractive takeover candidate .The hottest Pick in the pharma sector .GL


Antisense Therapeutics (ANP.AX)

Market Cap $13 Million
Cash $3 Million ( enough untill mid 2020)


Company Presentation
https://www.asx.com.au/asxpdf/20190625/pdf/44630r6yht8gkg.pdf


Could Antisense be the next multi-billion Duchenne Muscular Dystrophy biotech?
https://unauthorised investment advice/health/could-antisense-be-the-next-multi-billion-duchenne-muscular-dystrophy-biotech/


Live Presentation



ASX Junior’s Flagship Immunomodulatory Drug Could Turn the Tide in Duchenne Muscular Dystrophy Treatment
https://www.nextbiotech.com.au/asx-juniors-flagship-immunomodulatory-drug-could-turn-the-tide-in-duchenne-muscular-dystrophy-treatment/

ANTISENSE THERAPEUTICS SUMMARY & VALUE DRIVERSAdvanced stage product pipeline –two compounds with positive Phase II clinical results published in high quality peer reviewed scientific journalsHighly regarded substantial shareholders –have increased their holdingsPhase II clinical trial in Duchenne Muscular Dystrophy (DMD) – ATL1102−Trial is fully enrolled, results expected Q4 CY2019−Phase IIb trial design and approval process to run in parallel, accelerating development of ATL1102−Drug potentially complementary to other DMD programs e.g. SareptaTherapeutics−Significantly ‘underserved market’ with comparable company benchmarks demonstrating substantial value creation potentialEstablishing Early Access Program (EAP) for acromegaly– ATL1103−Plan to provide ATL1103 to acromegaly patients under an EAP in Europe−Potential for income generation & partnering to further develop the compound

ANP.AX (Mkap €11 M) DMD P2 Daten im Q4 = MEGA ZOCK | wallstreet-online.de - Vollständige Diskussion unter:
https://www.wallstreet-online.de/diskussion/1308085-1-10/anp-ax-mkap-11-m-dmd-p2-daten-q4-mega-zock

ANTISENSE THERAPEUTICS SUMMARY & VALUE DRIVERS

Advanced stage product pipeline –two compounds with positive Phase II clinical results published in high quality peer reviewed scientific journalsHighly regarded substantial shareholders

–have increased their holdingsPhase II clinical trial in Duchenne Muscular Dystrophy (DMD)

– ATL1102−Trial is fully enrolled, results expected Q4 CY2019

−Phase IIb trial design and approval process to run in parallel, accelerating development of ATL1102

−Drug potentially complementary to other DMD programs e.g. SareptaTherapeutics

−Significantly ‘underserved market’ with comparable company benchmarks demonstrating substantial value creation potential

Establishing Early Access Program (EAP) for acromegaly

– ATL1103−Plan to provide ATL1103 to acromegaly patients under an EAP in Europe

−Potential for income generation & partnering to further develop the compound